Sigma-Aldrich's biological products and services business, Sigma Life Science has launched CompoZr Transporter Knockout human cell lines in a consumable, assay-ready plate format.
The efflux transporter knockout cell lines identify individual drug-transporter interactions, which is a component to understand the safety and efficacy characteristics of drug candidates.
Sigma Life Science market segment manager Paul Brooks said CompoZr Transporter Knockout human cell lines in new format allow customers to avoid handling and maintenance of cell lines leading to reduced operative costs and time.
''Meeting the demands of both the occasional and the high-throughput user, the new format helps to address many of the unmet needs for preclinical ADME screening, safety studies, and new regulatory guidelines in the United States and Europe," Brooks added.
The efflux transporter cell lines consist of three individual knockouts, MDR1, MRP2 and BCRP and double knockouts MDR1:MRP2, MDR1:BCRP and MRP2:BCRP, which are delivered to the customer in a plate format.
The industry's present assays for drug-transporter interactions use chemical inhibitors, which usually interact with multiple transporters simultaneously and provide ambiguous information.
